SecBot SecBot

IKT

Inhibikase Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001750149 Biotech & Drug Discovery
$1.51 −0.01 (−0.66%)
Oct 27 4:00 PM ET · prev $1.52
Market cap
$227.4M
Micro cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$5.50
+264% · range $1.50–8.00
Next earnings
Nov 12
in 16 days · EPS est. −$0.13
1 year
−3.2%
from $1.56 · Oct 27
30 days
−26.3%
from $2.05
52-week range
$1.41–2.52
−40% from high · low Dec 2
Avg volume 20D
621.4K
Oct 14 spike 1.58M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL Inhibikase Therapeutics announced the resignation of director Dennis Berman and the appointment of Scott…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 19 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Median target $5.50 (+264%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.090 → −$0.125 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    29% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCADD4,028,102$8.2M
VANGUARD PORTFOLIO MANAGEMENT LLCADD809,490$1.6M
Bank of New York Mellon CorpADD303,126$615.3K
JONES FINANCIAL COMPANIES LLLPDOUBLED128,491$245.4K
RHUMBLINE ADVISERSDOUBLED120,014$243.6K
MORGAN STANLEYTRIM114,006$231.4K
BANK OF AMERICA CORP /DE/TRIM108,024$219.3K
FMR LLCADD103,727$210.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy5Buy7Hold1Sell0Strong Sell0
12-month targets · 10 analysts

Price is inside the target range. Median implies +264%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 13, 2026Chardan Capital
INITIATE
INITIATENeutral
Jun 10, 2026Oppenheimer
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 19, 2026
Wasserman Scott M.
Director
AWARD310,000 sh
Jul 30, 2026
BERMAN DENNIS N
Director
EXERCISE$27.5K
Jul 29, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
OTHER18,030,000 sh
Jul 29, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
OTHER18,030,000 sh
Jun 26, 2026
Canner David
Director
AWARD155,000 sh
Jun 26, 2026
Kush Arvind
Director
AWARD155,000 sh
Jun 26, 2026
Munshi Amit
Director
AWARD155,000 sh
Jun 26, 2026
Aurentz Vincent
Director
AWARD155,000 sh

Earnings setup

Estimates
Nov 12
reports in 16 days
−$0.13
EPS estimate, this quarter
−39%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.16–-$0.11-10.3%$0.00
Next Q-$0.13-$0.16–-$0.11-9.3%$187.5K
Current FY-$0.40-$0.45–-$0.33+10.1%$187.5K
Next FY-$0.42-$0.48–-$0.37+2.9%$250.0K

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
Inhibikase Therapeutics announced the resignation of director Dennis Berman and the appointment of Scott Wasserman…
8-K — Impact 3/10
Oct 20, 2026 Other
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In
Oct 19, 2026 Insider
Wasserman Scott M. was granted 310,000 shares
Director
Oct 2, 2026 Press
Inhibikase Therapeutics granted 128,000 non-qualified stock options to two newly-hired non-executive employees as an…
Impact 2/10
Aug 11, 2026 SEC
Inhibikase Therapeutics reported Q2 2026 net loss of $0.11 per share, in line with the year-ago period but with a net…
PRESS-RELEASE — Impact 5/10
Jul 30, 2026 Insider
BERMAN DENNIS N acquired via exercise 21,854 shares
Director @ $1.26 ($27.5K)
Jul 29, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. disposed of 18,030,000 shares
10%+ Owner
Jul 23, 2026 SEC
Inhibikase Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its lead candidate IKT-001 for…
8-K — Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
IKT Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 20, 2026
Press release
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...
Oct 2, 2026
Activist
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that…
Aug 12, 2026
Earnings date
IKT Q2 2026 Earnings Scheduled — 2026-08-12
Aug 11, 2026
Earnings
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage…
Jul 2, 2026
Press release
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that…

SecBot reports

9 filings · 1 press release · 2 bullish · 1 bearish · 1 mixed · 5 neutral
All IKT filing & press-release reports (10)